Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/19755
Title: Molecular Imaging Using PET/CT for Radiation Therapy Planning for Adult Cancers: Current Status and Expanding Applications.
Authors: McKay, Michael J;Taubman, Kim L;Foroudi, Farshad;Lee, Sze Ting;Scott, Andrew M
Affiliation: School of Cancer Medicine, Latrobe University, Melbourne, Victoria, Australia
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia
Department of Radiation Oncology, Olivia Newton John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Department of Medical Imaging, St Vincent's Hospital, Fitzroy, Victoria, Australia
Issue Date: 15-Nov-2018
EDate: 2018-03-21
Citation: International journal of radiation oncology, biology, physics 2018; 102(4): 783-791
Abstract: Accurate tumor delineation is a priority in radiation therapy (RT). Metabolic imaging has a key and evolving role in target volume selection and delineation. This is especially so for non-small cell lung cancer, squamous cell cancer of the head and neck, and lymphoma, for which positron emission tomography/computed tomography (PET/CT) is complimentary to structural imaging modalities, not only in delineating primary tumors, but also often in revealing previously undiagnosed regional nodal disease. At some sites, PET/CT has been confirmed to enable target size reduction compared with structural imaging alone, with enhanced normal tissue sparing and potentially allowing for dose escalation. These contributions often dramatically affect RT strategies. However, some limitations exist to the use of fluorodeoxyglucose-PET in RT planning, including its relatively poor spatial resolution and partial voluming effects for small tumors. A role is developing for contributions from metabolic imaging to RT planning at other tumor sites and exciting new applications for the use of non-fluorodeoxyglucose metabolic markers for RT planning.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19755
DOI: 10.1016/j.ijrobp.2018.03.013
ORCID: 0000-0001-8387-0965
0000-0001-8641-456X
0000-0002-6656-295X
PubMed URL: 30353883
Type: Journal Article
Review
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.